Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 168

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Implications of LINE1 Methylation for Bladder Cancer Risk in Women

Open access
Wilhelm, Charlotte S., Kelsey, Karl T., Butler, Rondi, Plaza, Silvia, Gagne, Luc, Zens, M. Scot, Andrew, Angeline S., Morris, Steven, Nelson, Heather H., Schned, Alan R., Karagas, Margaret R., Marsit, Carmen J.·2010·Clinical Cancer Research

Abstract

Purpose: Epigenetic alterations including changes to cellular DNA methylation levels contribute to carcinogenesis and may serve as powerful biomarkers of the disease. This investigation sought to determine whether hypomethylation at the long interspersed nuclear elements (LINE1), reflective of the level of global DNA methylation, in peripheral blood–derived DNA is associated with increased risk of bladder cancer. Experimental Design: LINE1 methylation was measured from blood-derived DNA obtained from participants of a population-based incident case-control study of bladder cancer in New Hampshire. Bisulfite-modified DNA was pyrosequenced to determine LINE1 methylation status; a total of 285 cases and 465 controls were evaluated for methylation. Results: Being in the lowest LINE1 methylation decile was associated with a 1.8-fold increased risk of bladder cancer [95% confidence interval (95% CI), 1.12-2.90] in models controlling for gender, age, and smoking, and the association was stronger in women than in men (odds ratio, 2.48; 95% CI, 1.19-5.17 in women; and odds ratio, 1.47; 95% CI, 0.79-2.74 in men). Among controls, women were more likely to have lower LINE1 methylation than men (P = 0.04), and levels of arsenic in the 90th percentile were associated with reduced LINE1 methylation (P = 0.04). Conclusions: LINE1 hypomethylation may be an important biomarker of bladder cancer risk, especially among women. Clin Cancer Res; 16(5); 1682–9

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-09-2983

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 168

Metadata

Authors
Wilhelm, C. S., Kelsey, K. T., Butler, R., Plaza, S., Gagne, L., Zens, M. S., Andrew, A. S., Morris, S., Nelson, H. H., Schned, A. R., Karagas, M. R., & Marsit, C. J.
Venue
Clinical Cancer Research
Published
2010-02-28
Volume
16
Issue
5
Pages
1682-1689
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2105672290
Cited by
168
References
4
FWCI
9.33
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Implications of LINE1 Methylation for Bladder Cancer Risk in Women. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-09-2983
The paper
Wilhelm, C. S., Kelsey, K. T., Butler, R., Plaza, S., Gagne, L., Zens, M. S., Andrew, A. S., Morris, S., Nelson, H. H., Schned, A. R., Karagas, M. R., & Marsit, C. J. (2010). Implications of LINE1 Methylation for Bladder Cancer Risk in Women. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-09-2983

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.